Target intelligence / Profile preview

Amyloid-beta protein N-terminal epitope (Aβ N-terminal epitope)

Target
Aβ N-terminal epitope
Molecular classification
Peptide, Antigen, Amyloid protein
01

Overview

The Amyloid-beta (Aβ) N-terminal epitope refers to the amino-terminal sequence of the Aβ peptide, typically encompassing residues 1 through 16, which is generated by the proteolytic cleavage of the amyloid precursor protein (APP) (Miles et al., 2011; DOI: 10.1038/srep00131). This region is highly accessible and serves as a primary target for passive immunotherapy in Alzheimer's disease because it remains exposed across various Aβ species, including soluble oligomers and insoluble fibrils (Sevigny et al., 2016; DOI: 10.1038/nature19323). Monoclonal antibodies such as aducanumab and lecanemab bind to this epitope to facilitate the clearance of amyloid plaques from the brain, primarily through microglial-mediated phagocytosis (van Dyck et al., 2023; DOI: 10.1056/NEJMoa2212948). Some therapies, like donanemab, specifically target post-translationally modified versions of this epitope, such as N-terminal pyroglutamate (pGlu3-Aβ), which is found exclusively in aggregated plaques (Mintun et al., 2021; DOI: 10.1056/NEJMoa2100708). By reducing the accumulation of these toxic aggregates, these therapies aim to slow cognitive decline and preserve neurological function in patients with early-stage Alzheimer's disease. However, targeting the N-terminus is frequently associated with Amyloid-Related Imaging Abnormalities (ARIA), which include brain edema (ARIA-E) and microhemorrhages (ARIA-H), requiring careful clinical monitoring (Sperling et al., 2011; DOI: 10.1016/j.jalz.2011.05.2351).

Other names
Abeta N-terminusAβ1-xAmyloid-beta peptide N-terminal domainN-terminal Amyloid-betaN3pG Amyloid-beta
02

Mechanism of action

Monoclonal antibodies bind to the N-terminal epitope of amyloid-beta (Aβ) peptides, which facilitates the clearance of existing amyloid plaques via Fc-receptor-mediated microglial phagocytosis and prevents the further aggregation of soluble Aβ monomers into neurotoxic oligomers and fibrils (Sevigny et al., 2016; DOI: 10.1038/nature19323; van Dyck et al., 2023; DOI: 10.1056/NEJMoa2212948).

03

Biological functions

Protein aggregationNeurotoxicitySynaptic dysfunction
04

Disease associations

Alzheimer's diseaseCerebral amyloid angiopathy
05

Safety considerations

Amyloid-related imaging abnormalities with edema (ARIA-E)Amyloid-related imaging abnormalities with hemorrhage (ARIA-H)Infusion-related reactionsCerebral macrohemorrhage
06

Interacting drugs

Aducanumab

4 more in the full profile.

07

Biomarkers

Amyloid PET imagingCerebrospinal fluid (CSF) Aβ42/Aβ40 ratioPlasma p-tau181Plasma p-tau217MRI for ARIA monitoring

Beyond the preview

Go deeper on Amyloid-beta protein N-terminal epitope (Aβ N-terminal epitope).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amyloid-beta protein N-terminal epitope (Aβ N-terminal epitope).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call